AI assistant
Krystal Biotech, Inc. — Director's Dealing 2017
Sep 25, 2017
31006_dirs_2017-09-25_b6bee51f-fd78-4437-8fa1-51926cbe3878.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3/A — Form 3/A
Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2017-09-19
Reporting Person: Krishnan Suma (Director, Chief Operating Officer, 10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Convertible Preferred Stock | $ | Common Stock (112162) | Indirect |
Footnotes
F1: The Series A convertible preferred stock will automatically convert on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering.
F2: These shares were incorrectly included in the Non-Derivative Securities table in the reporting person's original Form 3, filed September 19, 2017.
F3: The Krishnan Family Trust beneficially owns 112,162 shares of Series A convertible preferred stock. The reporting person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.